American Oncology Institute (AOI) in India has unveiled the Ethos Radiotherapy system, which is driven by artificial intelligence (AI).
Manufactured by Varian Medical Systems in the US, the system deploys an integrated suite of tools for the entire adaptive workflow ranging from initial planning to on-couch adaptation and treatment monitoring.
It is integrated with Varian’s surface guidance system called IDENTIFY, which enables the identification of real-time changes in tumour position while the treatment is underway, ETHealthworld.com reports.
IDENTIFY technology also helps capture the movement in internal and external anatomy at the time of each treatment. It also helps guide through the setup and position of the patient in the treatment room with the help of visual assistance.
The system offers personalisation capabilities by adapting real-time treatment plans based on the location of the tumour and changing patient anatomy.
It allows for enhancing pre-treatment plans besides adapting to real-time changes during the treatment by attaining insights through AI-enhanced image segmentation and surface motion sensors.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEthos applies automated dose accumulation and forecasting for monitoring the progress of the treatment.
Furthermore, it can be used along with existing treatments such as immunotherapy, targeted therapy and chemotherapy.
The system has the capability to target cancer cells in any region of the body, including the lungs, brain and liver and delivers an accurate dose of radiation to target and destroy cancer cells while sparing healthy cells.